Development and Application of an Artificial Intelligence-driven Accurate Identification Model for Gastric Cancer Lymph Node Metastasis

Launched by HEBEI MEDICAL UNIVERSITY · Aug 1, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on improving the way doctors detect and treat gastric cancer, which is a type of stomach cancer. The study is developing a new system that uses artificial intelligence (AI) to help identify whether cancer has spread to the lymph nodes, small glands that help fight infection. Knowing if the cancer has spread is important because it helps doctors decide on the best treatment options for patients. A team of specialists, including cancer doctors and AI experts, will work together to create and test this system using images and lab results from patients.

To participate in this trial, you need to be at least 18 years old and have been diagnosed with gastric cancer, either for the first time or if it has come back. You should also have some signs that the cancer might involve your lymph nodes. If you are pregnant, have certain severe health issues, or have used an AI system for this kind of diagnosis before, you won't be eligible to join. Participants will undergo regular tests, and the AI system's predictions will be compared to traditional methods to see if it can improve early detection and treatment outcomes for gastric cancer. This study could change how gastric cancer is diagnosed and treated in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosis of Gastric Cancer: Confirmed diagnosis of gastric cancer, either newly diagnosed or recurrent.
• • 2. Lymph Node Involvement: Suspected or confirmed involvement of lymph nodes, as indicated by imaging studies or pathology reports.
• • 3. Age: Patients aged 18 years or older.
• • 4. Performance Status: An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, indicating a functional status that allows participation in the study.
• • 5. Informed Consent: Ability to provide written informed consent to participate in the study.
• Exclusion Criteria:
• • 1. Pregnancy or Lactation: Pregnant or lactating women, due to potential risks to the fetus or infant.
• • 2. Severe Comorbid Conditions: Presence of severe comorbid medical conditions that could interfere with the study or pose additional risks.
• • 3. Previous AI-Driven Diagnostic Intervention: Prior use of any AI-driven diagnostic models specifically for gastric cancer lymph node metastasis.
• • 4. Inability to Comply: Inability or unwillingness to comply with study procedures, including follow-up visits and data collection.
• • 5. Mental or Cognitive Impairment: Conditions that impair the ability to provide informed consent or participate effectively in the study.